Clinical Trial Update: Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing extended-release and immediate-release pramipexole to placebo in early Parkinson disease, assessing efficacy, safety, and tolerability…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Mirapex (pramipexole)
• Mirapex ER (pramipexole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Early Parkinson Disease (Early PD) | Phase 3 | Status: COMPLETED | Results posted: 2010-04-15